Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.63 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.47 |
| ▸ | SCN2B | O60939 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16319313 | 0.89 | SCN9A (0.64) | SCN9ASCN5ASCN2BSCN1B | |
| SCHEMBL679997 | 0.85 | SCN9A (0.68) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL680391 | 0.85 | SCN9A (0.68) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL680507 | 0.84 | SCN9A (0.67) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL680161 | 0.82 | SCN9A (0.72) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL16175141 | 0.82 | SCN9A (0.59) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL16319491 | 0.82 | SCN9A (0.68) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL680617 | 0.81 | SCN9A (0.74) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL16175152 | 0.81 | SCN9A (0.63) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL16319452 | 0.81 | SCN9A (0.66) | SCN9ASCN5ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | SCN9A 29/4885SCN5A 27/4885SCN2B 15/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | SCN9A 32/4885SCN5A 30/4885SCN2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.